Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients

BACKGROUND: Hepatic steatosis is a common form of cystic fibrosis associated liver disease (CFLD) seen in an estimated 15%-60% of patients with cystic fibrosis (CF). The pathophysiology and health implications of hepatic steatosis in cystic fibrosis remain largely unknown. In the general population,...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutney, Katherine, Donnola, Shannon B, Flask, Chris A, Gubitosi-Klug, Rose, O’Riordan, MaryAnn, McBennett, Kimberly, Sferra, Thomas J, Kaminski, Beth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Observational Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960296/
https://www.ncbi.nlm.nih.gov/pubmed/31966908
http://dx.doi.org/10.4254/wjh.v11.i12.761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6960296/
https://www.ncbi.nlm.nih.gov/pubmed/31966908
http://dx.doi.org/10.4254/wjh.v11.i12.761

Ejemplares similares